S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Wall Street Pushing a 'Crypto Revolution' - Will You Miss Out… AGAIN? (Ad)
MarketBeat Week in Review – 2/19 - 2/23
A collection of the insights Warren Buffett offered in his annual letter Saturday
Wall Street Pushing a 'Crypto Revolution' - Will You Miss Out… AGAIN? (Ad)
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
Macron booed by French farmers who blame him for not doing enough to support agriculture
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Wall Street Pushing a 'Crypto Revolution' - Will You Miss Out… AGAIN? (Ad)
MarketBeat Week in Review – 2/19 - 2/23
A collection of the insights Warren Buffett offered in his annual letter Saturday
Wall Street Pushing a 'Crypto Revolution' - Will You Miss Out… AGAIN? (Ad)
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
Macron booed by French farmers who blame him for not doing enough to support agriculture
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Wall Street Pushing a 'Crypto Revolution' - Will You Miss Out… AGAIN? (Ad)
MarketBeat Week in Review – 2/19 - 2/23
A collection of the insights Warren Buffett offered in his annual letter Saturday
Wall Street Pushing a 'Crypto Revolution' - Will You Miss Out… AGAIN? (Ad)
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
Macron booed by French farmers who blame him for not doing enough to support agriculture
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Wall Street Pushing a 'Crypto Revolution' - Will You Miss Out… AGAIN? (Ad)
MarketBeat Week in Review – 2/19 - 2/23
A collection of the insights Warren Buffett offered in his annual letter Saturday
Wall Street Pushing a 'Crypto Revolution' - Will You Miss Out… AGAIN? (Ad)
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
Macron booed by French farmers who blame him for not doing enough to support agriculture
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover
NASDAQ:ATRC

AtriCure (ATRC) Stock Price, News & Analysis

$33.56
-0.44 (-1.29%)
(As of 02/23/2024 ET)
Today's Range
$32.91
$34.00
50-Day Range
$31.71
$37.31
52-Week Range
$29.67
$59.61
Volume
418,285 shs
Average Volume
575,792 shs
Market Capitalization
$1.60 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$55.57

AtriCure MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
65.6% Upside
$55.57 Price Target
Short Interest
Bearish
4.66% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.52mentions of AtriCure in the last 14 days
Based on 10 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.71) to ($0.44) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.33 out of 5 stars

Medical Sector

526th out of 942 stocks

Surgical & Medical Instruments Industry

62nd out of 90 stocks


ATRC stock logo

About AtriCure Stock (NASDAQ:ATRC)

AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, the company sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

ATRC Stock Price History

ATRC Stock News Headlines

AtriCure (NASDAQ:ATRC) Downgraded to "Sell" at StockNews.com
Disturbing Truth About Biden's New Program To Seize Your Cash
A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.
UBS Group Boosts AtriCure (NASDAQ:ATRC) Price Target to $58.00
Stifel Nicolaus Trims AtriCure (NASDAQ:ATRC) Target Price to $42.00
AtriCure (NASDAQ:ATRC) Stock Price Down 6% on Analyst Downgrade
AtriCure Full Year 2023 Earnings: EPS Beats Expectations
Free Stock Analysis Report: See The True Value of Any Stock
Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation.
AtriCure price target raised by $1 at UBS, here's why
Cracking The Code: Understanding Analyst Reviews For AtriCure
Recap: AtriCure Q4 Earnings
AtriCure Q4 2023 Earnings Preview
AtriCure's Earnings: A Preview
Atricure’s Strong Growth and Positive Outlook Justify Buy Rating
Key Takeaways From AtriCure Analyst Ratings
See More Headlines
Receive ATRC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AtriCure and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/15/2024
Today
2/25/2024
Next Earnings (Estimated)
5/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Current Symbol
NASDAQ:ATRC
CUSIP
04963C20
Employees
1,050
Year Founded
2000

Price Target and Rating

Average Stock Price Target
$55.57
High Stock Price Target
$68.00
Low Stock Price Target
$42.00
Potential Upside/Downside
+65.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-30,440,000.00
Pretax Margin
-7.48%

Debt

Sales & Book Value

Annual Sales
$399.24 million
Book Value
$9.80 per share

Miscellaneous

Free Float
46,160,000
Market Cap
$1.60 billion
Optionable
Optionable
Beta
1.40

Social Links

Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report














ATRC Stock Analysis - Frequently Asked Questions

Should I buy or sell AtriCure stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AtriCure in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ATRC shares.
View ATRC analyst ratings
or view top-rated stocks.

What is AtriCure's stock price target for 2024?

5 Wall Street research analysts have issued 1-year target prices for AtriCure's stock. Their ATRC share price targets range from $42.00 to $68.00. On average, they anticipate the company's share price to reach $55.57 in the next twelve months. This suggests a possible upside of 65.6% from the stock's current price.
View analysts price targets for ATRC
or view top-rated stocks among Wall Street analysts.

How have ATRC shares performed in 2024?

AtriCure's stock was trading at $35.69 at the beginning of the year. Since then, ATRC stock has decreased by 6.0% and is now trading at $33.56.
View the best growth stocks for 2024 here
.

Are investors shorting AtriCure?

AtriCure saw a increase in short interest in January. As of January 31st, there was short interest totaling 2,220,000 shares, an increase of 15.0% from the January 15th total of 1,930,000 shares. Based on an average daily trading volume, of 547,700 shares, the short-interest ratio is currently 4.1 days.
View AtriCure's Short Interest
.

When is AtriCure's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024.
View our ATRC earnings forecast
.

How were AtriCure's earnings last quarter?

AtriCure, Inc. (NASDAQ:ATRC) released its quarterly earnings data on Thursday, February, 15th. The medical device company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.22) by $0.01. The medical device company earned $106.50 million during the quarter, compared to analysts' expectations of $103.68 million. AtriCure had a negative net margin of 7.62% and a negative trailing twelve-month return on equity of 7.55%. The firm's quarterly revenue was up 21.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.09) earnings per share.

What guidance has AtriCure issued on next quarter's earnings?

AtriCure updated its FY 2024 earnings guidance on Monday, January, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $459.0 million-$466.0 million, compared to the consensus revenue estimate of $454.7 million.

What is Michael Carrel's approval rating as AtriCure's CEO?

38 employees have rated AtriCure Chief Executive Officer Michael Carrel on Glassdoor.com. Michael Carrel has an approval rating of 100% among the company's employees. This puts Michael Carrel in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 93.0% of employees surveyed would recommend working at AtriCure to a friend.

What other stocks do shareholders of AtriCure own?
Who are AtriCure's major shareholders?

AtriCure's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (10.05%), First Light Asset Management LLC (2.85%), Nuveen Asset Management LLC (2.16%), Dimensional Fund Advisors LP (2.11%), TimesSquare Capital Management LLC (2.06%) and Fiera Capital Corp (1.86%). Insiders that own company stock include Angela L Wirick, Angela L Wirick, David D Jr Grumhaus, Douglas J Seith, Justin J Noznesky, Karen Prange, Karl S Dahlquist, Maggie Yuen, Mark A Collar, Mark A Collar, Regina E Groves, Salvatore Privitera, Scott William Drake, Sven Wehrwein, Tonya Austin and Vinayak Doraiswamy.
View institutional ownership trends
.

How do I buy shares of AtriCure?

Shares of ATRC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does AtriCure have any subsidiaries?
The following companies are subsidiares of AtriCure: SentreHEART.
Read More
This page (NASDAQ:ATRC) was last updated on 2/25/2024 by MarketBeat.com Staff